Another study supported these findings and indicated that solely peripherally active CB1 inverse agonists/antagonists had therapeutic potential in obesity because of their high efficacy in normalizing the related metabolic abnormalities, including insulin resistance and fatty liver [64]. The gene discussed is CNR1; the disease is Obesity.